eMedicine Specialties > Emergency Medicine > Trauma & Orthopedics

Abdominal Trauma, Penetrating: Treatment & Medication

Author: Paul A Testa, MD, Resident, Department of Emergency Medicine, New York University Medical Center, Bellevue Hospital
Coauthor(s): Eric Legome, MD, Chair, Department of Emergency Medicine, St Vincent's Hospital, Manhattan; Lewis J Kaplan, MD, FACS, FCCM, FCCP, Director, SICU and Surgical Critical Care Fellowship, Associate Professor, Department of Surgery, Section of Trauma, Surgical Critical Care, and Surgical Emergencies, Yale University School of Medicine
Contributor Information and Disclosures

Updated: Jul 28, 2008

Treatment

Prehospital Care

  • The scope of care that paramedics deliver at the scene of the injury has evolved in parallel with the changing standard of care in the hospital setting.
    • Because most deaths occurred from exsanguination associated with prehospital hypotension, trauma system response is designed to minimize care in the field and expedite transport to the emergency department and to reduce the time to definitive care.
    • Aggressive intravenous fluid administration to maintain or reach normotension is discouraged in patients with penetrating injury unless the patient manifests severe shock or prolonged transport is expected.
  • Prehospital personnel must be well trained in properly assessing patients and in transporting them to the closest appropriate facility or trauma center. The receiving hospital should be notified as soon as possible by radio or ground line to give the ED time to prepare and to alert the appropriate staff. The mode of transportation also must be considered. In an urban setting with multiple appropriate facilities, the best transport is probably by ground. In the rural setting, where the closest facility is 25 minutes or more away, trauma patients' best chance for survival may be transport by air ambulance.

Emergency Department Care

Missed intra-abdominal injuries are among the most frequent causes of potentially preventable trauma deaths. The evaluation and management of abdominal trauma is dependent on mechanism and location of injury, hemodynamic and neurologic status of the patient, associated injuries, and institutional resources. A team leader should direct resuscitation and coordinate all care. Depending on the institution, it may be an emergency physician, trauma surgeon, or one of their supervised residents. Given the potential for significant injury, a junior level physician should not lead care without direct oversight.

  • ED care of the patient with penetrating trauma revolves around several important concepts. On arrival, as the ABCDE's are being assessed, a few brief interventions should be performed. The patient should be placed on a cardiac monitor, pulse oximeter, and 100% nonrebreather oxygen mask. Intravenous access should be established.
    • Assessment and treatment of the basics of trauma life support
      • Airway: Patients with severe shock or loss of ability to control their airway should be intubated to ensure appropriate oxygenation or ventilation. In general, occult cervical spine injury in penetrating trauma is highly unlikely. Unless there are clear deficits or associated blunt injury, cervical collars are rarely necessary and may hinder resuscitation.
      • Breathing: Tube thoracostomy or needle decompression should be undertaken immediately for patients with obvious pneumothorax. If the patient is otherwise stable, he or she should have a chest radiograph performed in the trauma room. An upright positioned radiograph during expiration may provide the best evidence of pneumothorax. Ultrasonography for pneumothorax has been shown to be highly accurate and may be used as the initial test, but it should be followed by a radiograph at some point.
      • Circulation: The route of intravenous access is important. Large-bore peripheral intravenous catheters in the upper extremities are the resuscitation lines of choice. These allow for rapid volume/blood infusion versus a central line where the infusion rate is slower. Still, extensive debate exists in the literature on the amount and end points for resuscitation prior to definitive control of hemorrhage. Both animal data and several studies in humans are looking at "permissive hypotension," that is, actively or passively allowing the blood pressure to remain in the hypotensive ranges less than 90 mm Hg. The theory is that this will prevent disruption of clot and dilution of clotting factors while maintaining adequate blood viscosity. While no definite consensus exists, prevailing thought seems to promote limited resuscitation with avoidance of attempting to raise blood pressure to normal or near-normal levels until hemorrhage is definitively controlled.
      • Deficits: A rapid and brief evaluation for neurologic deficits should be conducted.
      • Exposure: All patients with penetrating trauma should be fully undressed. Complete exposure and head-to-toe visualization of the patient is mandatory in a patient with penetrating abdominal trauma. This includes the buttocks, posterior part of the legs, scalp, posterior part of the neck, and perineum. There is little to be gained by practicing spinal immobilization unless spinal injury is obvious.
      • Depending on the initial assessment, and in all seriously injured patients, a Foley catheter should be placed if possible to monitor urine output and to check for hematuria. In addition, a nasogastric tube (NGT) or orogastric tube (OGT) should be inserted to evaluate for intragastric blood and to decompress the stomach so as to reduce aspiration risk. Appropriate laboratory specimens should be immediately sent to the laboratory for evaluation.
  • After the initial evaluation, further evaluation depends on the hemodynamics and mechanism of wounds. Briefly, options are as follows:
    • Stab wounds
      • Unstable patients or those with clear-cut peritonitis should undergo exploratory laparotomy.
      • If stable, patients may have local wound exploration to ascertain if the peritoneum was violated. If unable to perform or if flank or thoracoabdominal wounds are present, other methods must be used. DPL is still an option, but it is currently being used less frequently. A positive FAST examination result has a high positive predictive value for a therapeutic laparotomy, but a negative FAST examination result cannot be relied upon to rule out injury.
      • If thoracoabdominal, a chest radiograph should be obtained. If no signs of diaphragmatic injury are present, laparoscopy is usually advocated; although some surgeons will elect not too perform this on a right-sided wound given the low likelihood of delayed complications.
      • The use of CT scan is still controversial; some centers use it as a screening test in patients with anterior stab wounds, while others feel the cost-benefit ratio is not justified. A triple contrast CT should be performed on patients with penetrating flank wounds.
      • Essentially all nonoperative patients, except those who have a wound that clearly does not penetrate the abdomen, should be observed for serial examinations. Literature is beginning to support a shortened time frame of 12 hours, but most centers use about 24 hours.
    • Gunshot wounds
      • All unstable gunshot wounds should proceed emergently to the operating room (OR). Abdominal and other radiographs (depending on possible bullet course and number of wounds) should be taken at some point during the patient's care to account for all bullets.
      • In the past, all gunshot wounds that were clearly nontangential were taken to the OR for exploration. An increasing body of literature supports CT imaging, either triple contrast or just intravenous contrast alone to evaluate for intra-abdominal or retroperitoneal injury. This has been shown to significantly decrease the need for laparotomy without a concurrent increase in morbidity. All hollow viscus injuries need emergent laparotomy; however, isolated liver or spleen injuries are sometimes observed or undergo angioembolization.
  • Patient disposition relates to the type of facility and to the mechanism of and potential for injury. The most common post-ED disposition for patients with penetrating abdominal trauma is to the OR. Any patient with an obvious reason for laparotomy (eg, evisceration, rigid abdomen, hypotension) should be taken directly to the OR following initial evaluation and resuscitation in the ED. Some facilities do not have a surgical or OR team available 24 hours a day. In this case, these patients must be transferred to an appropriate facility. Similar concerns occur if the patient's injuries overwhelm the available resources at the receiving facility.

Consultations

In general, consultation by a general or trauma surgeon should be undertaken for victims of penetrating trauma.

  • At some centers, trauma surgeons perform the majority of operative repair, while at others, consultants may be involved as individual injuries are identified. For example, a vascular surgeon may repair major arterial and venous injuries or a urologist may address injuries to the bladder, kidneys, and ureters.
  • Trauma surgeons, even if not directly performing care, should oversee the patient's care and postoperative course.

Medication

In general, medications used to treat victims of penetrating abdominal trauma fall into discrete categories. Analgesics, anxiolytics, antimicrobials (skin and enteric flora), immune boosters (tetanus booster), and neuromuscular blockers comprise the major classes of pharmacotherapeutic agents used for these patients.

Analgesics

Pain control is essential to quality patient care. Appropriate and sufficient pain control is important. Concerns still exist regarding pain control in patients undergoing observation. A reasonable protocol should be developed by institutions in consultation with the trauma service or consulting surgeon. Postoperatively, analgesics are essential to ensure patient comfort, promote pulmonary toilet, and enable physical therapy regimens.


Morphine sulfate (MS Contin, Oramorph SR, Duramorph)

Drug of choice for analgesia due to reliable and predictable effects, safety profile, and ease of reversibility with naloxone.
Various IV doses are used; commonly titrated until desired effect is obtained.

Adult

Initial dose: 0.1 mg/kg IV/IM
Maintenance dose: 5-20 mg/70 kg IV/IM q4h
Relatively hypovolemic patients: Start with 2 mg IV/IM; reassess the hemodynamic effects of dose

Pediatric

Neonates: 0.05-0.2 mg/kg/dose IV prn
Children: 0.1-0.2 mg/kg/dose IV/IM q2-4h prn

Phenothiazines may antagonize analgesic effects of opiate agonists; tricyclic antidepressants, MAOIs, and other CNS depressants may potentiate adverse effects

Documented hypersensitivity; hypotension; respiratory depression; potentially compromised airway in which establishing rapid airway control would be difficult; nausea; emesis; constipation; urinary retention

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in hypotension, respiratory depression, nausea, emesis, constipation, urinary retention, atrial flutter, and other supraventricular tachycardias; has vagolytic action and may increase ventricular response rate


Fentanyl citrate (Duragesic, Sublimaze)

Potent narcotic analgesic with much shorter half-life than morphine sulfate. Common choice for procedural sedation analgesia. Excellent for analgesic action of short duration during anesthesia and immediate postoperative period. Excellent choice for pain management and sedation with short duration (30-60 min) and easy to titrate. Easily and quickly reversed by naloxone.
After initial dose, subsequent doses should not be titrated more frequently than q3h or q6h thereafter.
Most patients are controlled with 72-h dosing intervals when using transdermal dosage form, although some patients require 48-h dosing intervals.

Adult

0.5-1 mcg/kg/dose IV/IM q30-60min
Alternatively, apply a 25 mcg/h transdermal system q48-72h

Pediatric

<2 years: 2-3 mcg/kg/dose IV/IM q30-60min
2-12 years: 1-2 mcg/kg/dose q1h
>12 years: Administer as in adults

Phenothiazines may antagonize analgesic effects of opiate agonists; tricyclic antidepressants may potentiate adverse effects of fentanyl when both drugs are used concurrently

Documented hypersensitivity; hypotension; potentially compromised airway in which it would be difficult to establish rapid airway control

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in hypotension, respiratory depression, constipation, nausea, emesis, and urinary retention; idiosyncratic reaction, known as chest wall rigidity syndrome, may require neuromuscular blockade to increase ventilation

Anxiolytics

Patients with painful injuries usually experience significant anxiety. Anxiolytics allow the clinician to administer a smaller analgesic dose to achieve the same effect.


Lorazepam (Ativan)

Sedative hypnotic with short onset of effects and relatively long half-life.
By increasing the action of GABA, a major inhibitory neurotransmitter in the brain, may depress all levels of CNS, including limbic and reticular formation.
Excellent choice when patient must be sedated for longer than 24 h.

Adult

Initial dose: 2 mg IV total or 0.044 mg/kg IV, whichever is smaller
For greater lack of recall: 0.05 mg/kg IV q4-8h; not to exceed 4 mg/dose

Pediatric

0.05-0.1 mg/kg IV slowly over 2-5 min; may repeat a dose of 0.5 mg/kg IV slowly

Toxicity of benzodiazepines in CNS increases when used concurrently with alcohol, phenothiazines, barbiturates, and MAOIs

Documented hypersensitivity; preexisting CNS depression; hypotension; narrow-angle glaucoma

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in renal or hepatic impairment, myasthenia gravis, organic brain syndrome, or Parkinson disease


Midazolam hydrochloride (Versed)

Shorter-acting benzodiazepine sedative-hypnotic useful in patients requiring immediate and/or short-term sedation. Also useful for its amnestic effects. Frequently used for procedural sedation

Adult

Procedural sedation:
Loading dose: 0.05-0.2 mg IV over 2 min
Maintenance dose: Infuse 1-2 mcg/kg/min IV titrated to the desired effect
Dosing range: 0.4-6 mcg/kg/min
Alternatively, 0.07-0.08 mg/kg IM
Average total dose is 5 mg administered up to 1 h before surgery

Pediatric

Sedation, anxiolysis, or amnesia: 0.1-0.15 mg/kg IV over 2-3 min; may use up to 0.5 mg/kg in very anxious patients
Intranasal route may be used for pediatric sedation (to age 2 y); doses are 1-2 mg and are limited by volume delivered

Sedative effects may be antagonized by theophyllines; narcotics and erythromycin may accentuate sedative effects due to decreased clearance

Documented hypersensitivity; preexisting hypotension; narrow-angle glaucoma; sensitivity to propylene glycol (the diluent)

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in congestive heart failure, pulmonary disease, renal impairment, and hepatic failure

Antibiotics

Antibiotic prophylaxis is proven to reduce postoperative surgical infections after penetrating abdominal trauma.

The Eastern Association for the Surgery of Trauma (EAST) Practice Management Guidelines Work Group recently published evidence-based consensus guidelines addressing the use and duration of antimicrobial prophylaxis after penetrating abdominal trauma. They recommended, in the absence of hollow viscus injury, patients should receive a single dose of a broad-spectrum antimicrobial agent that provides both aerobic and anaerobic coverage. No specific agent is recommended, but it may be a single agent with beta-lactam coverage or combination therapy with an aminoglycoside and clindamycin or metronidazole. In patients with a hollow viscus injury, antimicrobial prophylaxis should be extended to 24 hours.

While some controversies still exist regarding therapy for seriously injured patients, for the emergency physician, the key point is to start antibiotics in the ED. If the patient requires emergent laparotomy and must be rapidly transported, it may be done upon arrival to the OR.


Cefotetan (Cefotan)

Second-generation cephalosporin with activity against some gram-positive cocci, gram-negative rod infections, and anaerobic bacteria. Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits final transpeptidation step of peptidoglycan synthesis, resulting in cell wall death.
Infections caused by cephalosporin- or penicillin-resistant gram-negative bacteria may respond to cefotetan.
Antibiotics have proven effective in decreasing rate of postoperative wound infection and improving outcome in patients with intraperitoneal infection and septicemia.

Adult

2 g IV once prior to surgery, followed by 4 doses of 2 g q12h

Pediatric

Not established

Probenecid may increase effects of cefotetan; coadministration with aminoglycosides or furosemide may increase nephrotoxicity (closely monitor renal function)

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections, and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy


Metronidazole hydrochloride (Flagyl)

Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Used in combination with other antimicrobial agents (except for Clostridium difficile enterocolitis).

Adult

Loading dose: Infuse 15 mg/kg IV over 1 h or 1 g for a 70-kg adult
Maintenance dose: 6 h following the loading dose, infuse 7.5 mg/kg IV over 1 h q6-8h or 500 mg for a 70-kg adult; not to exceed 4 g/d

Pediatric

Administer as in adults (using body weight)
15-30 mg/kg/d IV divided bid/tid for 7 d or 40 mg/kg PO once; not to exceed 2 g/d

Cimetidine may increase toxicity; may increase effects of anticoagulants; may increase toxicity of lithium and phenytoin; disulfiramlike reaction may occur with orally ingested ethanol

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy


Gentamicin sulfate (Garamycin, Gentacidin)

Aminoglycoside antibiotic for gram-negative coverage. Used in combination with an agent against gram-positive organisms and one that covers anaerobes.
Not the drug of choice. Consider if penicillins or other less toxic drugs are contraindicated, when clinically indicated, and in mixed infections caused by susceptible staphylococci and gram-negative organisms.
Dosing regimens are numerous; adjust dose based on creatinine clearance and changes in volume of distribution. May be administered IV/IM.

Adult

Serious infections and normal renal function: 3 mg/kg/d IV q8h
Loading dose and maintenance dose: 1-2.5 mg/kg IV and 1-1.5 mg/kg IV q8h, respectively
Extended dosing regimen for life-threatening infections: 5 mg/kg/d IV/IM q6-8h
Follow each regimen by at least a trough level drawn on the third or fourth dose (0.5 h before dosing); may draw a peak level 0.5 h after 30-min infusion

Pediatric

<5 years: 2.5 mg/kg/dose IV/IM q8h
>5 years: 1.5-2.5 mg/kg/dose IV/IM q8h or 6-7.5 mg/kg/d IV divided q8h; not to exceed 300 mg/d; monitor as in adults

Coadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents (prolonged respiratory depression may occur); coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly)

Documented hypersensitivity; non–dialysis-dependent renal insufficiency

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Narrow therapeutic index (not intended for long-term therapy); caution in renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment


Vancomycin hydrochloride (Vancocin, Lyphocin)

Potent antibiotic directed against gram-positive organisms and active against enterococcal species. Useful in treatment of septicemia and skin-structure infections. Indicated for patients who cannot receive or who are unresponsive to penicillins and cephalosporins or who have infections with resistant staphylococci. For penetrating abdominal injuries, it is combined with an agent active against enteric flora and/or anaerobes.
To avoid toxicity, current recommendation is to assay trough levels after third dose drawn 0.5 h prior to next dosing. Use creatinine clearance to adjust dose in patients with renal impairment.
Used in conjunction with gentamicin for prophylaxis in penicillin-allergic patients undergoing GI or GU procedures.

Adult

500 mg to 2 g/d IV divided tid/qid for 7-10 d

Pediatric

40 mg/kg/d IV divided tid/qid for 7-10 d

Erythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in renal failure, neutropenia; red man syndrome (not an allergic reaction) is caused by too-rapid IV infusion (dose administered over a few min), but this rarely occurs when dose administered over 2-h period or by PO or IP routes


Ampicillin sodium-sulbactam sodium (Unasyn)

Drug combination of beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens.

Adult

1.5 (1 g ampicillin + 0.5 g sulbactam) to 3 g (2 g ampicillin + 1 g sulbactam) IV/IM q6-8h; not to exceed 4 g/d sulbactam or 8 g/d ampicillin

Pediatric

<3 months: Not established
3 months to 12 years: 100-200 mg ampicillin/kg/d (150-300 mg Unasyn) IV divided q6h
>12 years: Administer as in adults

Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction

Neuromuscular blocking agents

Many patients with penetrating abdominal trauma require urgent airway control.


Succinylcholine chloride (Anectine Chloride, Anectine Flo-Pack)

Prototypical depolarizing neuromuscular blocker that is ultra–short-acting and predictable in onset (<1 min) and duration (4-6 min). Highly ionized, relatively fat-insoluble; does not readily cross placenta.
Pediatric patients must be pretreated with atropine to avoid bradycardia and cardiac arrest. May also occur in adults but more commonly is associated with administration of either a higher dose or a second dose.

Adult

Intubation: 0.6 mg/kg IV
Dose should be individualized and may range between 0.3-1.1 mg/kg

Pediatric

Administer as in adults

Concomitant administration with nondepolarizing muscle relaxants may enhance neuromuscular blocking action; activity is prolonged when concurrently administered with oxytocin, quinidine, beta-blockers, and procainamide

Documented hypersensitivity; malignant hyperthermia; myopathies associated with elevated serum creatine phosphokinase levels; narrow-angle glaucoma; hyperkalemia; malignant hyperthermia; penetrating eye injuries

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in paraplegia, hyperkalemia, severe burns, and deficiencies in plasma cholinesterase; bolus administration in infants and children has been associated with malignant arrhythmias and hyperkalemic rhabdomyolysis


Vecuronium bromide (Norcuron)

Prototypic, nondepolarizing, neuromuscular blocking agent that reliably results in muscular paralysis. For intubation and maintenance of paralysis, a continuous infusion may be used.
Infants are more sensitive to neuromuscular blockade activity; recovery is prolonged by 50%, although the same dose is used. Not recommended for use in neonates.

Adult

0.08-0.1 mg/kg IV
Dose may be reduced to 0.05 mg/kg if patient has been treated with succinylcholine
Maintenance dose for paralysis: 0.025-0.1 mg/kg/h IV; can be titrated to desired train-of-four response (commonly 2 of 4 twitches)

Pediatric

Neonates: Not recommended
7 weeks to 1 year: 0.08-0.1 mg/kg/dose followed by maintenance dose of 0.05-0.1 mg/kg q1h prn
1-10 years: May require higher initial dose and more frequent supplementation
>10 years: Administer as in adults

Neuromuscular blockade is enhanced when used concurrently with inhalational anesthetics; renal or hepatic failure, as well as concomitant administration of steroids, may result in prolonged blockade despite withdrawal of agent

Documented hypersensitivity; myasthenia gravis or related syndromes

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Small doses may have profound effects in myasthenia gravis or myasthenic syndrome

Immune enhancement

For penetrating abdominal trauma resulting in wounds contaminated with either dirt or debris or for wounds caused by metallic objects carrying a risk of Clostridium tetani infection. Tetanus results from elaboration of an exotoxin from C tetani. A booster injection in previously immunized individuals is recommended to prevent this potentially lethal syndrome. Patients who may not have been immunized against C tetani products (eg, immigrants) should receive tetanus immune globulin (Hyper-Tet).


Tetanus toxoid aluminum phosphate

Induces active immunity against tetanus in selected patients. The immunizing agents of choice for most adults and children >7 y are tetanus and diphtheria toxoids. Necessary to administer booster doses to maintain tetanus immunity throughout life.
Pregnant patients should receive only tetanus toxoid not a diphtheria antigen-containing product.
In children and adults, may administer into deltoid or midlateral thigh muscles. In infants, preferred site of administration is the mid thigh laterally.

Adult

Primary immunization: 0.5 mL IM; administer 2 injections 4-8 wk apart and a third dose 6-12 mo after second injection
Booster dose: 0.5 mL q10y

Pediatric

Administer as in adults

Because of poor immune response, patients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent use of medication with systemic chloramphenicol since it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction is nevertheless clinically insignificant and does not preclude its concurrent use)

Documented hypersensitivity; history of any type of neurologic symptoms or signs following administration of this product; FDA recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are an important cause of provocative poliomyelitis

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Do not use to treat actual tetanus infections or for immediate prophylaxis of unimmunized individuals (instead use tetanus antitoxin, preferably human tetanus immune globulin); diminished antibody response to active immunization may be seen in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy is discontinued; routine immunization of symptomatic and asymptomatic persons infected with HIV is recommended

More on Abdominal Trauma, Penetrating

Overview: Abdominal Trauma, Penetrating
Differential Diagnoses & Workup: Abdominal Trauma, Penetrating
Treatment & Medication: Abdominal Trauma, Penetrating
Follow-up: Abdominal Trauma, Penetrating
Multimedia: Abdominal Trauma, Penetrating
References

References

  1. Velmahos GC, Constantinou C, Tillou A, et al. Abdominal computed tomographic scan for patients with gunshot wounds to the abdomen selected for nonoperative management. J Trauma. Nov 2005;59(5):1155-60; discussion 1160-1. [Medline].

  2. Ahmed N, Whelan J, Brownlee J, et al. The contribution of laparoscopy in evaluation of penetrating abdominal wounds. J Am Coll Surg. Aug 2005;201(2):213-6. [Medline].

  3. Aldemir M, Tacyildiz I, Girgin S. Predicting factors for mortality in the penetrating abdominal trauma. Acta Chir Belg. Aug 2004;104(4):429-34. [Medline].

  4. Alzamel HA, Cohn SM. When is it safe to discharge asymptomatic patients with abdominal stab wounds?. J Trauma. Mar 2005;58(3):523-5.

  5. Arikan S, Kocakusak A, Yucel AF, Adas G. A prospective comparison of the selective observation and routine exploration methods for penetrating abdominal stab wounds with organ or omentum evisceration. J Trauma. Mar 2005;58(3):526-32. [Medline].

  6. Biffl WL, Harrington DT, Majercik SD, et al. The evolution of trauma care at a level I trauma center. J Am Coll Surg. Jun 2005;200(6):922-9. [Medline].

  7. Bir CA, Stewart SJ, Wilhelm M. Skin penetration assessment of less lethal kinetic energy munitions. J Forensic Sci. Nov 2005;50(6):1426-9. [Medline].

  8. Bozorgzadeh A, Pizzi WF, Barie PS, et al. The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg. Feb 1999;177(2):125-31. [Medline].

  9. Brown CV, Velmahos GC, Neville AL, et al. Hemodynamically "stable" patients with peritonitis after penetrating abdominal trauma: identifying those who are bleeding. Arch Surg. Aug 2005;140(8):767-72. [Medline].

  10. Chol YB, Lim KS. Therapeutic laparoscopy for abdominal trauma. Surg Endosc. Mar 2003;17(3):421-7. [Medline].

  11. Cotton BA, Nance ML. Penetrating trauma in children. Semin Pediatr Surg. May 2004;13(2):87-97. [Medline].

  12. Delgado G Jr, Barletta JF, Kanji S, et al. Characteristics of prophylactic antibiotic strategies after penetrating abdominal trauma at a level I urban trauma center: a comparison with the East guidelines. J Trauma. Oct 2002;53(4):673-8. [Medline].

  13. Demetriades D, Murray J, Charalambides K, et al. Trauma fatalities: time and location of hospital deaths. J Am Coll Surg. Jan 2004;198(1):20-6. [Medline].

  14. Demetriades D, Velmahos G. Technology-driven triage of abdominal trauma: the emerging era of nonoperative management. Annu Rev Med. 2003;54:1-15. [Medline].

  15. Drost TF, Rosemurgy AS, Kearney RE, Roberts P. Diagnostic peritoneal lavage. Limited indications due to evolving concepts in trauma care. Am Surg. Feb 1991;57(2):126-8. [Medline].

  16. Eddy VA, Morris JA, Rozycki GS. Trauma and pregnancy. In: The Textbook of Penetrating Trauma. Lippincott Williams & Wilkins; 1996:695-701.

  17. Ertekin C, Yanar H, Taviloglu K, et al. Unnecessary laparotomy by using physical examination and different diagnostic modalities for penetrating abdominal stab wounds. Emerg Med J. Nov 2005;22(11):790-4. [Medline].

  18. Fabian TC, Croce MA. Abdominal trauma, including indications for celiotomy. J Trauma. 2000;1583-602.

  19. Fabian TC, Croce MA, Stewart RM, et al. A prospective analysis of diagnostic laparoscopy in trauma. Ann Surg. May 1993;217(5):557-64; discussion 564-5. [Medline].

  20. Ferrada R, Birolini D. New concepts in the management of patients with penetrating abdominal wounds. Surg Clin North Am. Dec 1999;79(6):1331-56. [Medline].

  21. Friese RS, Coln CE, Gentilello LM. Laparoscopy is sufficient to exclude occult diaphragm injury after penetrating abdominal trauma. J Trauma. Apr 2005;58(4):789-92. [Medline].

  22. Green SM. Is there evidence to support the need for routine surgeon presence on trauma patient arrival?. Ann Emerg Med. May 2006;47(5):405-11. [Medline].

  23. Ivatury RR, Porter JM, Simon RJ, et al. Intra-abdominal hypertension after life-threatening penetrating abdominal trauma: prophylaxis, incidence, and clinical relevance to gastric mucosal pH and abdominal compartment syndrome. J Trauma. Jun 1998;44(6):1016-21; discussion 1021-3. [Medline].

  24. Jansen JO, Logie JR. Diagnostic peritoneal lavage - an obituary. Br J Surg. May 2005;92(5):517-8. [Medline].

  25. Kahdi FU. Role of ultrasound in penetrating abdominal trauma: a prospective clinical study. J Trauma. 2000;50(3):475-9.

  26. Kaplan LJ, Santora TA, Blank-Reid CA, Trooskin SZ. Improved emergency department efficiency with a three-tier trauma triage system. Injury. Sep 1997;28(7):449-53. [Medline].

  27. Kuczkowski KM, Ispirescu JS, Benumof JL. Trauma in pregnancy: anesthetic management of the parturient with multiple gun shot wounds to the gravid uterus and fetal injury. J Trauma. Feb 2003;54(2):420. [Medline].

  28. Leppaniemi A, Haapiainen R. Diagnostic laparoscopy in abdominal stab wounds: a prospective, randomized study. J Trauma. Oct 2003;55(4):636-45.

  29. Luchette FA, Borzotta AP, Croce MA, et al. Practice management guidelines for prophylactic antibiotic use in penetrating abdominal trauma: the EAST Practice Management Guidelines Work Group. J Trauma. Mar 2000;48(3):508-18. [Medline].

  30. Mattox KL, Goetzl L. Trauma in pregnancy. Crit Care Med. Oct 2005;33(10 Suppl):S385-9. [Medline].

  31. Murphy JT, Hall J, Provost D. Fascial ultrasound for evaluation of anterior abdominal stab wound injury. J Trauma. Oct 2005;59(4):843-6.

  32. Nicholas JM, Rix EP, Easley KA, et al. Changing patterns in the management of penetrating abdominal trauma: the more things change, the more they stay the same. J Trauma. Dec 2003;55(6):1095-108; discussion 1108-10. [Medline].

  33. Pryor JP, Reilly PM, Dabrowski GP, et al. Nonoperative management of abdominal gunshot wounds. Ann Emerg Med. Mar 2004;43(3):344-53. [Medline].

  34. Richards CF, Mayberry JC. Initial management of the trauma patient. Crit Care Clin. Jan 2004;20(1):1-11. [Medline].

  35. Schurink GW, Bode PJ, van Luijt PA, van Vugt AB. The value of physical examination in the diagnosis of patients with blunt abdominal trauma: a retrospective study. Injury. May 1997;28(4):261-5. [Medline].

  36. Sebesta J. Special lessons learned from iraq. Surg Clin North Am. Jun 2006;86(3):711-26. [Medline].

  37. Simon RJ, Rabin J, Kuhls D. Impact of increased use of laparoscopy on negative laparotomy rates after penetrating trauma. J Trauma. Aug 2002;53(2):297-302; discussion 302. [Medline].

  38. Swan KG, Swan RC. Principles of ballistics applicable to the treatment of gunshot wounds. Surg Clin North Am. Apr 1991;71(2):221-39. [Medline].

  39. Todd SR. Critical concepts in abdominal injury. Crit Care Clin. Jan 2004;20(1):119-34. [Medline].

  40. Tsikitis V, Biffl WL, Majercik S, et al. Selective clinical management of anterior abdominal stab wounds. Am J Surg. Dec 2004;188(6):807-12.

  41. Udobi KF, Rodriguez A, Chiu WC, Scalea TM. Role of ultrasonography in penetrating abdominal trauma: a prospective clinical study. J Trauma. Mar 2001;50(3):475-9. [Medline].

Further Reading

Keywords

gunshot wound, GSW, stab wounds, SW, shotgun wounds, impalement, penetrating trauma, penetrating abdominal wounds, penetrating abdominal trauma, intra-abdominal hemorrhage, peritonitis, intra-abdominal injury, peritoneal injury, abdominal injury, abdominal trauma, intraperitoneal injury

Contributor Information and Disclosures

Author

Paul A Testa, MD, Resident, Department of Emergency Medicine, New York University Medical Center, Bellevue Hospital
Paul A Testa, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Emergency Medicine Residents Association
Disclosure: Nothing to disclose.

Coauthor(s)

Eric Legome, MD, Chair, Department of Emergency Medicine, St Vincent's Hospital, Manhattan
Eric Legome, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, Council of Emergency Medicine Residency Directors, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Lewis J Kaplan, MD, FACS, FCCM, FCCP, Director, SICU and Surgical Critical Care Fellowship, Associate Professor, Department of Surgery, Section of Trauma, Surgical Critical Care, and Surgical Emergencies, Yale University School of Medicine
Lewis J Kaplan, MD, FACS, FCCM, FCCP is a member of the following medical societies: American Association for the Surgery of Trauma, American College of Surgeons, Association for Academic Surgery, Association for Surgical Education, Connecticut State Medical Society, Eastern Association for the Surgery of Trauma, International Trauma Anesthesia and Critical Care Society, Society for the Advancement of Blood Management, Society of Critical Care Medicine, and Surgical Infection Society
Disclosure: Nothing to disclose.

Medical Editor

Roy Alson, MD, PhD, FACEP, FAAEM, Associate Professor, Department of Emergency Medicine, Wake Forest University School of Medicine; Medical Director, Forsyth County EMS; Deputy Medical Advisor, North Carolina Office of EMS; Associate Medical Director, North Carolina Baptist AirCare
Roy Alson, MD, PhD, FACEP, FAAEM is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, National Association of EMS Physicians, North Carolina Medical Society, Society for Academic Emergency Medicine, and Wilderness Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Jon Mark Hirshon, MD, MPH, Associate Professor, Department of Emergency Medicine, University of Maryland School of Medicine
Jon Mark Hirshon, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Public Health Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.